AVIR
vs
S&P 500
AVIR
S&P 500
Over the past 12 months, AVIR has underperformed S&P 500, delivering a return of -3% compared to the S&P 500's +14% growth.
Stocks Performance
AVIR vs S&P 500
Performance Gap
AVIR vs S&P 500
Performance By Year
AVIR vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Atea Pharmaceuticals Inc
Glance View
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 59 full-time employees. The company went IPO on 2020-10-30. The firm is focused on discovering, developing, and commercializing antiviral therapeutics to enhance the lives of patients suffering from life-threatening viral infections. The firm is engaged in the development of product candidates to treat COVID-19, hepatitis C virus (HCV), dengue and respiratory syncytial virus (RSV). The firm is developing bemnifosbuvir (AT-527), which is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor for the treatment of COVID-19. The company is developing bemnifosbuvir and ruzasvir, an investigational nonstructural protein 5A (NS5A) inhibitor for the treatment of chronic HCV infection. The firm is also developing AT-752, an oral, purine nucleotide prodrug for the treatment of dengue. AT-527 is designed to inhibit viral replication by interfering with viral RNA polymerase.
